Antithrombotic treatment of asymptomatic carotid atherosclerosis: a medical dilemma

Intern Emerg Med. 2020 Oct;15(7):1169-1181. doi: 10.1007/s11739-020-02347-7. Epub 2020 May 13.

Abstract

Carotid artery atherosclerosis (CAAS) is a common finding in asymptomatic subjects evaluated for cardiovascular (CV)-risk stratification. Besides the careful control of CV-risk factors, antithrombotic agents, and in particular aspirin, may be considered for primary prevention in patients at CV-risk. However, there is strong controversy on the use of aspirin in primary prevention. Even if several studies confirmed the association between CAAS and CV-events, CAAS is not universally recognized as an independent risk factor and the choice to use aspirin as primary prevention in these patients remains a medical dilemma. Here we review the available evidence on the prognostic value of asymptomatic CAAS for major CV-events and on the utility of antithrombotic agents in this population. We conclude that the detection of asymptomatic CAAS can not be considered as a direct indication to carry out primary prophylaxis with antithrombotic drugs, and the choice to use aspirin should be made only after the careful estimate of the individual's CV-and hemorrhagic risk.

Keywords: Antiplatelet; Aspirin; Asymptomatic carotid artery stenosis; Cardiovascular risk; Primary prevention.

Publication types

  • Review

MeSH terms

  • Aspirin / therapeutic use*
  • Cardiovascular Diseases / etiology
  • Cardiovascular Diseases / prevention & control
  • Carotid Artery Diseases / complications*
  • Carotid Artery Diseases / diagnostic imaging
  • Carotid Artery Diseases / drug therapy*
  • Cerebrovascular Disorders / etiology
  • Cerebrovascular Disorders / prevention & control
  • Fibrinolytic Agents / therapeutic use*
  • Humans
  • Platelet Aggregation Inhibitors / therapeutic use*
  • Primary Prevention*
  • Risk Assessment
  • Risk Factors

Substances

  • Fibrinolytic Agents
  • Platelet Aggregation Inhibitors
  • Aspirin